miR-31 regulates energy metabolism and is suppressed in Tcells from patients with Sjogren's syndrome

被引:12
作者
Johansson, Alina [1 ,5 ]
Nyberg, William A. [1 ]
Sjostrand, Maria [1 ,6 ,7 ]
Moruzzi, Noah [4 ]
Bergman, Petra [2 ]
Khademi, Mohsen [2 ]
Andersson, Magnus [2 ,3 ]
Piehl, Fredrik [2 ,3 ]
Berggren, Per-Olof [4 ]
Covacu, Ruxandra [2 ]
Jagodic, Maja [2 ]
Espinosa, Alexander [1 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Unit Rheumatol,Dept Med, CMM L8 04, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Karolinska Univ Hosp, Ctr Mol Med, Unit Neuroimmunol,Dept Clin Neurosci, Stockholm, Sweden
[3] Karolinska Univ Hosp, Div Neurol, Stockholm, Sweden
[4] Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, Rolf Luft Res Ctr Diabet & Endocrinol, Stockholm, Sweden
[5] Uppsala Univ, Dept Med Sci, Sci Life Lab, Rheumatol, Uppsala, Sweden
[6] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
基金
瑞典研究理事会;
关键词
Autoimmunity; Interferons; Immune regulation; Metabolism; Rheumatology; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEPATITIS-C; INTERFERON; INTERLEUKIN-2; MICRORNAS; SIGNATURE; THERAPY; CELLS;
D O I
10.1002/eji.201747416
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic autoimmune diseases are characterized by the overexpression of type I IFN stimulated genes, and accumulating evidence indicate a role for type I IFNs in these diseases. However, the underlying mechanisms for this are still poorly understood. To explore the role of type I IFN regulated miRNAs in systemic autoimmune disease, we characterized cellular expression of miRNAs during both acute and chronic type I IFN responses. We identified a Tcell-specific reduction of miR-31-5p levels, both after intramuscular injection of IFN and in patients with Sjogren's syndrome (SjS). To interrogate the role of miR-31-51p in Tcells we transfected human CD4(+) Tcells with a miR-31-5p inhibitor and performed metabolic measurements. This identified an increase in basal levels of glucose metabolism after inhibition of miR-31-5p. Furthermore, treatment with IFN- also increased the basal levels of human CD4(+) T-cell metabolism. In all, our results suggest that reduced levels of miR-31-5p in Tcells of SjS patients support autoimmune T-cell responses during chronic type I IFN exposure.
引用
收藏
页码:313 / 322
页数:10
相关论文
共 26 条
  • [11] Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration
    La Rocca, Claudia
    Carbone, Fortunata
    De Rosa, Veronica
    Colamatteo, Alessandra
    Galgani, Mario
    Perna, Francesco
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Orefice, Giuseppe
    Cerillo, Ilaria
    Florio, Ciro
    Maniscalco, Giorgia Teresa
    Salvetti, Marco
    Centonze, Diego
    Uccelli, Antonio
    Longobardi, Salvatore
    Visconti, Andrea
    Matarese, Giuseppe
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 77 : 39 - 46
  • [12] Interferon-inducible effector mechanisms in cell-autonomous immunity
    MacMicking, John D.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2012, 12 (05) : 367 - 382
  • [13] 35-YEAR-OLD PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA DEVELOPING SYSTEMIC LUPUS-ERYTHEMATOSUS AFTER ALPHA-INTERFERON THERAPY
    MEHTA, ND
    HOOBERMAN, AL
    VOKES, EE
    NEELEY, S
    COTLER, S
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1992, 41 (02) : 141 - 142
  • [14] The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection
    Moffett, Howell F.
    Cartwright, Adam N. R.
    Kim, Hye-Jung
    Godec, Jernej
    Pyrdol, Jason
    Aijo, Tarmo
    Martinez, Gustavo J.
    Rao, Anjana
    Lu, Jun
    Golub, Todd R.
    Cantor, Harvey
    Sharpe, Arlene H.
    Novina, Carl D.
    Wucherpfennig, Kai W.
    [J]. NATURE IMMUNOLOGY, 2017, 18 (07) : 791 - +
  • [15] Interferon alpha-induced lupus - Proof of principle
    Niewold, Timothy B.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (03) : 131 - 132
  • [16] A changing treatment landscape for multiple sclerosis: challenges and opportunities
    Piehl, F.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2014, 275 (04) : 364 - 381
  • [17] Rönnblom L, 2016, CLIN EXP RHEUMATOL, V34, pS21
  • [18] The interferon signature in autoimmune diseases
    Ronnblom, Lars
    Eloranta, Maija-Leena
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (02) : 248 - 253
  • [19] SCHILLING PJ, 1991, CANCER, V68, P1536, DOI 10.1002/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO
  • [20] 2-B